Medtronic plc (MDT) stock analysis

Healthcare · Medical Devices

From the 10-K filed 2026-06-18

Business type: Franchise

How it makes money

Medtronic earns revenue by selling device-based medical therapies and services across three primary portfolios to healthcare systems, physicians, clinicians, and patients globally.

Medtronic operates through three reportable segments: the Cardiovascular Portfolio, the Neuroscience Portfolio, and the Medical Surgical Portfolio. These divisions develop, manufacture, distribute, and sell specialized medical devices and services to healthcare providers in more than 150 countries worldwide.

Profitability is driven by the successful adoption and scaling of inventive medical technologies, ongoing product innovation, and maintaining pricing power despite competitive pressures and government-driven procurement mechanisms like volume-based procurement initiatives.

What protects it: the moat

Medtronic relies on proprietary product design, patent protections, and ongoing technological innovation to maintain its competitive position against other medical device manufacturers.

The medical technology industry is characterized by rapid change resulting from technological advances, scientific discoveries, and competition from both large diversified companies and small specialized manufacturers. Management states that its ability to compete depends on factors including product performance, reliability, innovation, quality, and reimbursement approval from healthcare insurance providers.

However, the loss of patent protection can allow competitors to introduce reprocessed products or competitive devices that make existing product lines less competitive.

What growth costs

The filing does not detail specific ongoing capital expenditure requirements or total R&D budgets needed to sustain its product pipelines.

The provided text discusses management's strategy to accelerate innovation-driven growth and bring disruptive technology to large healthcare opportunities, but it does not disclose the specific financial figures required for ongoing capital investments, research and development expenses, or working capital needs.

What could damage it

Government-driven pricing and procurement mechanisms can force significant price concessions, which directly constrain revenue growth and compress profit margins.

When governments implement aggressive procurement mechanisms, such as national and provincial tender pricing programs or volume-based procurement initiatives in certain major markets, manufacturers face mandatory price cuts. These pricing pressures reduce realized unit economics and constrain profit generation across impacted product portfolios.

About Medtronic plc

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients in the United States, Ireland, and internationally. It operates through three segments: The Cardiovascular Portfolio, Neuroscience Portfolio, and Medical Surgical Portfolio. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves, left atrial appendage exclusion systems, extracorporeal membrane oxygenation (ECMO) systems and percutaneous coronary intervention products, percutaneous angioplasty balloons, and endovenous products. The Neuroscience Portfolio segment offers medical devices and implants, biologic solutions, spinal cord stimulation and brain modulation systems, implantable drug infusion systems, and interventional products, as well as nerve ablation system under the Accurian name. This segment offers its products for spinal surgeons, neurosurgeons, neurologists, pain management specialists, anesthesiologists, orthopedic surgeons, urologists, urogynecologists, and interventional radiologists, as well as ear, nose, and throat specialists, and energy surgical instruments. The Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure and electrosurgery products, AI-powered surgical video and analytics platform, robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology products, gastrointestinal and hepatologic diagnostics and therapies, and therapies to treat diseases and conditions, and patient monitoring and airway management products, as well as insulin pumps and consumables, continuous glucose monitoring systems, and sensors. Medtronic plc was founded in 1949 and is headquartered in Galway, Ireland.

More on MDT

Other companies in Medical Devices